Genmab A (GMAB) Receivables - Net (2023 - 2025)

Genmab A (GMAB) has disclosed Receivables - Net for 3 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 1644.62% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Dec 2025, up 1644.62%, and an annual FY2025 reading of $1.1 billion, up 1644.62% over the prior year.
  • Receivables - Net was $1.1 billion for Q4 2025 at Genmab A, up from $65.0 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $1.1 billion in Q4 2025 and bottomed at $65.0 million in Q4 2024.
  • Average Receivables - Net over 3 years is $647.3 million, with a median of $743.0 million recorded in 2023.
  • The sharpest move saw Receivables - Net crashed 91.25% in 2024, then soared 1644.62% in 2025.
  • Year by year, Receivables - Net stood at $743.0 million in 2023, then plummeted by 91.25% to $65.0 million in 2024, then skyrocketed by 1644.62% to $1.1 billion in 2025.
  • Business Quant data shows Receivables - Net for GMAB at $1.1 billion in Q4 2025, $65.0 million in Q4 2024, and $743.0 million in Q4 2023.